

## Appendix 3Y

### Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b> BARD1 Life Sciences Limited
<b>ABN</b> 58 009 070 384

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Dr Geoffrey Cumming
<b>Date of last notice</b>	24 August 2020

**Part 1 - Change of director's relevant interests in securities**

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Jamelys Superannuation Fund
<b>Date of change</b>	4 December 2020
<b>No. of securities held prior to change</b>	<ul style="list-style-type: none"> <li>- 88,347 ordinary fully paid shares – Jamelys Superannuation Fund (following the 1 for 30 share consolidation)</li> <li>- 27,413 ordinary fully paid shares – Dr Geoffrey Cumming (following the 1 for 30 share consolidation)</li> <li>- 52,000 unlisted BD1 incentive options – Dr Geoffrey Cumming (following the 1 for 30 share consolidation)</li> </ul>
<b>Class</b>	Ordinary Fully Paid Shares
<b>Number acquired</b>	9,333
<b>Number disposed</b>	N/A

---

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	An average of \$0.7571 per ordinary share
<b>No. of securities held after change</b>	- 97,680 ordinary fully paid shares – Jamelys Superannuation Fund - 27,413 ordinary fully paid shares – Dr Geoffrey Cumming - 52,000 unlisted BD1 incentive options – Dr Geoffrey Cumming
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-market purchase

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

### Part 3 – <sup>+</sup>Closed period

<sup>+</sup> See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.